Clinical trials: Neoadjuvant Treatment
Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
This study aims to evaluate the effectiveness and safety of a preoperative treatment (called neoadjuvant therapy) combining four drugs-nab-paclitaxel, oxaliplatin, S-1, and sintilimab-for patients with locally advanced…
- Conditions
- Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
- Trial name
- YOUNG-NEOS (NCT07018063)
- Testing
- nab-paclitaxel, oxaliplatin, S-1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- zhoujing
Thyroid Neoplasms
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI ± TKI) can render locally…
- Trial name
- NCT07010393
- Testing
- Dabrafenib, Trametinib, Selpercatinib
- Where
- China
- Volunteers
- 335 people
- Sponsor
- Fujian Medical University
Locally Advanced Rectal Cancer (LARC)
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study plans to include LARC patients receiving neoadjuvant therapy at this center, conducting PET/CT and PET/MR examinations before treatment, and PET/MR examinations before surgery after neoadjuvant therapy.
- Trial name
- NCT06653452
- Testing
- 18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Squamour Cell Cancer
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study.
- Trial name
- NCT06814158
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colon Neoplasm
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.
- Trial name
- ICONIC (NCT05914389)
- Testing
- Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Oral Squamous Cell Carcinoma, Head and Neck Cancer
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
This is a phase 2, open-label, single-arm clinical trial evaluating neoadjuvant therapy with Becotatug vedotin (MRG003) combined with Pucotenlimab (HX008) in patients with previously untreated, resectable stage III-IVA oral…
- Conditions
- Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
- Trial name
- NCT07766889
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Lymphocytic Leukemia, Chronic
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
This single arm study will assess the efficacy and safety of MabThera + chlorambucil as induction therapy, followed in responders by maintenance therapy or observation in elderly patients with previously untreated chronic…
- Trial name
- NCT00738374
- Testing
- rituximab [MabThera/Rituxan], chlorambucil
- Where
- 20 sites in Italy
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Triple Negative Breast Cancer
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
This is a phase II, single-centered, open-label, single-armed study in patients with early triple-negative breast cancer that will evaluate the pathological complete response (pCR) rate of a non-anthracycline-based…
- Trial name
- NCT06407310
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Volunteers
- 25 people
- Sponsor
- Tel Aviv Medical Center
Glioblastoma Multiforme
Neoadjuvant Nivolumab in Glioblastoma
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
- Trial name
- Neo-nivo (NCT02550249)
- Testing
- Nivolumab
- Where
- Spain
- Volunteers
- 29 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC)
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for…
- Conditions
- Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
- Trial name
- NCT07386158
- Testing
- Pucotenlimab combination with Vorolanib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sun Yat-sen University
Differentiated Thyroid Cancer
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer.
- Trial name
- NCT05989425
- Testing
- surufatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma HNSCC
Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial
This study compares two short pre-surgery treatments for locally advanced head and neck squamous cell cancer to see which one keeps the cancer from coming back longer.
- Trial name
- SHINE (NCT07371897)
- Testing
- Docetaxel and Cisplatin, Toripalimab
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
RATIONALE: Preoperative 5-Fu based chemoradiation has become standard treatment for stage 2/3 rectal cancer. However whether these patients, especially T3N0-1M0 patients, really need radiation for local control after total…
- Trial name
- FOWARC (NCT01211210)
- Testing
- fluorouracil, fluorouracil, oxaliplatin
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy
Our hypothesis is that the doxorubicin eluting-beads currently used in hepato-oncology might be applicable to high-grade prostate cancer before radical prostatectomy.
- Trial name
- CAPEMCHAR (NCT04423913)
- Testing
- Administration of embolization beads
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Breast Cancer
Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses
Primary The purpose of this study is to evaluate tumour pathological complete response rate after six cycles of neoadjuvant docetaxel and cyclophosphamide in an Asian population. Secondary To assess: 1.
- Trial name
- NCT01540110
- Testing
- Neoadjuvant Docetaxel and Cyclophosphamide
- Where
- Singapore
- Volunteers
- 21 people
- Sponsor
- National Cancer Centre, Singapore
Locally Advanced Rectal Cancer
Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) is now considered as a standard treatment of locally advanced rectal adenocarcinomas, which correlates better local control and higher sphincter preservation rate.
- Trial name
- NCT01899118
- Testing
- Preoperative irradiation, Nimotuzumab, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Small Cell Lung Cancer
Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy
evaluate the predictive value of circulating neutrophil DNA methylation profiles, identified from the ALCINA 2 cohort, on pre-treatment blood samples (T0), for the histological response to neoadjuvant chemo-immunotherapy in…
- Trial name
- NEO-TAN (NCT06974097)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Montpellier
Promyelocytic Leukemia
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
ATRA is the standard of care for all patients with APL. The use of lower doses of ATRA has been shown since the 1990s to achieve therapeutic efficacy with doses of 25mg/m2/day.
- Trial name
- NCT05497310
- Testing
- Arsenic trioxide, all-trans retinoic acid
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Gastric Cancer, Adenocarcinoma
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
The aim of this study is to evaluate the efficacy of a neoadjuvant approach in patients with locally advanced gastric cancer and the identification of prognostic factors.
- Conditions
- Gastric Cancer, Adenocarcinoma, Effects of Chemotherapy, Surgery
- Trial name
- NCT02454647
- Testing
- Induction chemotherapy, Radiotherapy with concurrent chemotherapy, Salvage surgery
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
- Trial name
- PC-1 (NCT05993858)
- Testing
- 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.